Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 6904634, 12 pages
https://doi.org/10.1155/2017/6904634
Research Article

New Hydroxycinnamic Acid Esters as Novel 5-Lipoxygenase Inhibitors That Affect Leukotriene Biosynthesis

Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada E1A 3E9

Correspondence should be addressed to Mohamed Touaibia

Received 24 January 2017; Revised 3 May 2017; Accepted 8 May 2017; Published 7 June 2017

Academic Editor: Sandra Helena Penha Oliveira

Copyright © 2017 Luc H. Boudreau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Rådmark, O. Werz, D. Steinhilber, and B. Samuelsson, “5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease,” Biochimica et Biophysica Acta, vol. 1851, pp. 331–339, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Mehrabian, H. Allayee, J. Wong et al., “Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice,” Circulation Research, vol. 91, pp. 120–126, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Leff, W. W. Busse, D. Pearlman et al., “Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction,” The New England Journal of Medicine, vol. 339, pp. 147–152, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Chen, B. K. Lam, Y. Kanaoka et al., “Neutrophil-derived leukotriene B4 is required for inflammatory arthritis,” The Journal of Experimental Medicine, vol. 203, pp. 837–842, 2006, Rockefeller Univ Press. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Sarveswaran, D. Chakraborty, D. Chitale, R. Sears, and J. Ghosh, “Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells,” The Journal of Biological Chemistry, vol. 290, pp. 4994–5006, 2015, American Society for Biochemistry and Molecular Biology. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Wejksza, C. Lee-Chang, M. Bodogai et al., “Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α,” Journal of Immunology, vol. 190, pp. 2575–2584, 2013, American Association of Immunologists. View at Publisher · View at Google Scholar · View at Scopus
  7. S. K. Wculek and I. Malanchi, “Neutrophils support lung colonization of metastasis-initiating breast cancer cells,” Nature, vol. 528, pp. 413–417, 2015, Nature Research. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Hofmann and D. Steinhilber, “5-Lipoxygenase inhibitors: a review of recent patents (2010-2012),” Expert Opinion on Therapeutic Patents, vol. 23, pp. 895–909, 2013, Taylor & Francis. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Pergola and O. Werz, “5-Lipoxygenase inhibitors: a review of recent developments and patents,” Expert Opinion on Therapeutic Patents, vol. 20, pp. 355–375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Steinhilber and B. Hofmann, “Recent advances in the search for novel 5-lipoxygenase inhibitors,” Basic and Clinical Pharmacology and Toxicology, vol. 114, pp. 70–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Nelson, J. Kemp, W. Berger et al., “Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study,” Annals of Allergy, Asthma & Immunology, vol. 99, pp. 178–184, 2007. View at Publisher · View at Google Scholar
  12. E. Israel, P. Rubin, J. P. Kemp et al., “The effect of inhibition of 5-lipoxygenase by Zileuton in mild-to-moderate asthma,” Annals of Internal Medicine, vol. 119, pp. 1059–1066, 1993, American College of Physicians. View at Publisher · View at Google Scholar
  13. M. C. Liu, L. M. Dubé, and J. Lancaster, “Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group,” Journal of Allergy and Clinical Immunology, vol. 98, pp. 859–871, 1996. View at Publisher · View at Google Scholar
  14. O. Werz, “Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin,” Planta Medica, vol. 73, pp. 1331–1357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Huang, C.-P. Zhang, K. Wang, G. Q. Li, and F.-L. Hu, “Recent advances in the chemical composition of propolis,” Molecules, vol. 19, pp. 19610–19632, 2014, Multidisciplinary Digital Publishing Institute. View at Publisher · View at Google Scholar · View at Scopus
  16. A. P. Tiveron, P. L. Rosalen, M. Franchin et al., “Chemical characterization and antioxidant, antimicrobial, and anti-inflammatory activities of south Brazilian organic propolis,” PLoS One, vol. 11, article e0165588, 2016, Public Library of Science. Agbor G, editor. View at Publisher · View at Google Scholar · View at Scopus
  17. I. A. Freires, S. M. de Alencar, and P. L. Rosalen, “A pharmacological perspective on the use of Brazilian red propolis and its isolated compounds against human diseases,” European Journal of Medicinal Chemistry, vol. 110, pp. 267–279, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. O. K. Mirzoeva and P. C. Calder, “The effect of propolis and its components on eicosanoid production during the inflammatory response. Prostaglandins, leukotrienes and essential fatty acids,” Churchill Livingstone, vol. 55, pp. 441–449, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. M. F. Tolba, S. S. Azab, A. E. Khalifa, S. Z. Abdel-Rahman, and A. B. Abdel-Naim, “Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: a review on its anti-inflammatory, neuroprotective, hepatoprotective, and cardioprotective effects,” IUBMB Life, vol. 65, pp. 699–709, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. L. H. Boudreau, J. Maillet, L. M. LeBlanc et al., “Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes,” PLoS One, vol. 7, article e31833, 2012, Public Library of Science. Proost P, editor. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Doiron, B. Métayer, R. R. Richard et al., “Clicked cinnamic/caffeic esters and amides as radical scavengers and 5-lipoxygenase inhibitors,” International Journal of Medicinal Chemistry, vol. 2014, Article ID 931756, p. 12, 2014, Hindawi Publishing Corporation. View at Publisher · View at Google Scholar
  22. G. F. Sud'ina, O. K. Mirzoeva, M. A. Pushkareva, G. A. Korshunova, N. V. Sumbatyan, and S. D. Varfolomeev, “Caffeic acid phenethyl ester as a lipoxygenase inhibitor with antioxidant properties,” FEBS Letters, vol. 329, pp. 21–24, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. J. A. Doiron, L. M. LeBlanc, M. J. Hébert et al., “Structure-activity relationship of caffeic acid phenethyl ester analogs as new 5-lipoxygenase inhibitors,” Chemical Biology & Drug Design, vol. 89, pp. 514–528, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. J. T. Sanderson, H. Clabault, C. Patton et al., “Antiproliferative, antiandrogenic and cytotoxic effects of novel caffeic acid derivatives in LNCaP human androgen-dependent prostate cancer cells,” Bioorganic & Medicinal Chemistry, vol. 21, pp. 7182–7193, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. L. H. Boudreau, J. Bertin, P. P. Robichaud et al., “Novel 5-lipoxygenase isoforms affect the biosynthesis of 5-lipoxygenase products,” The FASEB Journal, vol. 25, pp. 1097–1105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Doiron, L. H. Boudreau, N. Picot, B. Villebonet, M. E. Surette, and M. Touaibia, “Synthesis and 5-lipoxygenase inhibitory activity of new cinnamoyl and caffeoyl clusters,” Bioorganic & Medicinal Chemistry Letters, vol. 19, pp. 1118–1121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. E. P. Allain, L. H. Boudreau, N. Flamand, and M. E. Surette, “The intracellular localisation and phosphorylation profile of the human 5-lipoxygenase Δ13 isoform differs from that of its full length counterpart,” PLoS One, vol. 10, article e0132607, 2015, Public Library of Science. Samant R, editor. View at Publisher · View at Google Scholar · View at Scopus
  28. P. P. Robichaud, S. J. Poirier, L. H. Boudreau et al., “On the cellular metabolism of the click chemistry probe 19-alkyne arachidonic acid,” Journal of Lipid Research, 2016, American Society for Biochemistry and Molecular Biology. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Böyum, “Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g,” Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum, vol. 97, pp. 77–89, 1968. View at Google Scholar
  30. N. Cloutier, A. Pare, R. W. Farndale et al., “Platelets can enhance vascular permeability,” Blood, vol. 120, pp. 1334–1343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. L. H. Boudreau, J. Maillet, L. B. LM et al., “Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes,” PloS One, vol. 7, article e31833-8, 2012, Proost P, editor. View at Publisher · View at Google Scholar · View at Scopus
  32. M. E. Surette, J. D. Winkler, A. N. Fonteh, and F. H. Chilton, “Relationship between arachidonate—phospholipid remodeling and apoptosis,” Biochemistry, vol. 35, pp. 9187–9196, 1996, American Chemical Society. View at Publisher · View at Google Scholar · View at Scopus
  33. G. M. Morris, R. Huey, W. Lindstrom et al., “AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, pp. 2785–2791, 2009, Wiley Subscription Services, Inc., A Wiley Company. View at Publisher · View at Google Scholar · View at Scopus
  34. G. M. Morris, D. S. Goodsell, M. E. Pique et al., AutoDock Version 4.2; Updated for Version 4.2.6, s.l.: The Scripps Research Institute, Molecular Graphics Laboratory, La Jolla, CA, USA, 2009.
  35. R. A. Laskowski and M. B. Swindells, “LigPlot+: multiple ligand–protein interaction diagrams for drug discovery,” Journal of Chemical Information and Modeling, vol. 51, pp. 2778–2786, 2011, American Chemical Society. View at Publisher · View at Google Scholar · View at Scopus
  36. L. H. Boudreau, N. Picot, J. Doiron et al., “Caffeoyl and cinnamoyl clusters with anti-inflammatory and anti-cancer effects. Synthesis and structure–activity relationship,” New Journal of Chemistry, vol. 33, pp. 1932–1940, 2009. View at Google Scholar
  37. N. C. Gilbert, S. G. Bartlett, M. T. Waight et al., “The structure of human 5-lipoxygenase,” Science, vol. 331, pp. 217–219, 2011, American Association for the Advancement of Science. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Rossi, C. Pergola, A. Koeberle et al., “The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages,” British Journal of Pharmacology, vol. 161, pp. 555–570, 2010, Blackwell Publishing Ltd. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Peters-Golden and W. R. Henderson, “Leukotrienes,” New England Journal of Medicine, vol. 357, pp. 1841–1854, 2007. View at Google Scholar
  40. T. Yokoyama, Y. Kosaka, and M. Mizuguchi, “Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin,” Journal of Medicinal Chemistry, vol. 57, pp. 8928–8935, 2014, American Chemical Society. View at Publisher · View at Google Scholar · View at Scopus
  41. O. Rådmark, O. Werz, D. Steinhilber, and B. Samuelsson, “5-Lipoxygenase: regulation of expression and enzyme activity,” Trends in Biochemical Sciences, vol. 32, pp. 332–341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. P. P. Robichaud, S. J. Poirier, L. H. Boudreau et al., “On the cellular metabolism of the click chemistry probe 19-alkyne arachidonic acid,” Journal of Lipid Research, vol. 57, pp. 1821–1830, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Gerstmeier, C. Weinigel, D. Barz, O. Werz, and U. Garscha, “An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis,” Biochimica et Biophysica Acta, vol. 1840, pp. 2961–2969, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. M. E. Surette, A. Odeimat, R. Palmantier, S. Marleau, P. E. Poubelle, and P. Borgeat, “Reverse-phase high-performance liquid chromatography analysis of arachidonic acid metabolites in plasma after stimulation of whole blood ex vivo,” Analytical Biochemistry, vol. 216, pp. 392–400, 1994. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Celli, L. K. Dragani, S. Murzilli, A. Tommaso Pagliani, and A. Poggi, “In vitro and in vivo stability of caffeic acid phenethyl ester, a bioactive compound of propolis,” Journal of Agricultural and Food Chemistry, vol. 55, pp. 3398–3407, 2007, American Chemical Society. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Satoh, P. Taylor, W. F. Bosron, S. P. Sanghani, M. Hosokawa, and B. N. La Du, “Current progress on esterases: from molecular structure to function,” Drug Metabolism and Disposition, vol. 30, pp. 488–493, 2002, American Society for Pharmacology and Experimental Therapeutics. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Wang, J. Pang, J. A. Maffucci et al., “Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats,” Biopharmaceutics & Drug Disposition, vol. 30, pp. 221–228, 2009, John Wiley & Sons, Ltd. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Yang, P. D. Bowman, S. M. Kerwin, and S. Stavchansky, “Development and validation of an LCMS method to determine the pharmacokinetic profiles of caffeic acid phenethyl amide and caffeic acid phenethyl ester in male Sprague–Dawley rats,” Biomedical Chromatography, vol. 28, pp. 241–246, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Hanke, F. Dehm, S. Liening et al., “Aminothiazole-featured Pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo,” Journal of Medicinal Chemistry, vol. 56, pp. 9031–9044, 2013, American Chemical Society. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Altavilla, L. Minutoli, F. Polito et al., “Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia,” British Journal of Pharmacology, vol. 167, pp. 95–108, 2012, Blackwell Publishing Ltd. View at Publisher · View at Google Scholar · View at Scopus